ReNerve Newsletter April 2020

ReNerve completed a capital raising in March 2020, with the company raising just over $1.1M in new equity. As a
result, the Company is well positioned to progress the NervAlignTM nerve cuff programme through to FDA submission
and approval, and progress our other key programmes into 2021.